These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 18803278)

  • 1. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
    Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
    Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
    Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
    Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
    Efird LE; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia.
    Pistulli R; Oberle V; Figulla HR; Yilmaz A; Pfeifer R
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):76-8. PubMed ID: 21076279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux: does it cause HIT? Can it treat HIT?
    Warkentin TE
    Expert Rev Hematol; 2010 Oct; 3(5):567-81. PubMed ID: 21083474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of anti-PF4/heparin antibodies and the HIT syndrome in cardiovascular medicine.
    Mattioli AV
    Semin Thromb Hemost; 2004 Jun; 30(3):291-5. PubMed ID: 15282651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.
    Modi C; Satani D; Cervellione KL; Cervantes J; Gintautas J
    Proc West Pharmacol Soc; 2009; 52():5-7. PubMed ID: 22128408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heparin induced thrombocytopenia type II after the use of low-molecular weight heparin. Case report and review of the literature].
    Franke J; Schaeper O; Kayser R; Mahlfeld K
    Unfallchirurg; 2003 Jan; 106(1):77-81. PubMed ID: 12552397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
    Warkentin TE; Cook RJ; Marder VJ; Sheppard JA; Moore JC; Eriksson BI; Greinacher A; Kelton JG
    Blood; 2005 Dec; 106(12):3791-6. PubMed ID: 16109780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of heparin-induced thrombocytopenia with fondaparinux.
    Harenberg J; Jörg I; Fenyvesi T
    Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis.
    Matsuo T; Kobayashi H; Matsuo M; Wanaka K; Nakamoto H; Matsushima H; Sakai R
    Pathophysiol Haemost Thromb; 2006; 35(6):445-50. PubMed ID: 17565238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HITlights: a career perspective on heparin-induced thrombocytopenia.
    Warkentin TE
    Am J Hematol; 2012 May; 87 Suppl 1():S92-9. PubMed ID: 22367928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.
    Walenga JM; Jeske WP; Prechel MM; Bacher P; Bakhos M
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():69-80. PubMed ID: 15085468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).
    Rota E; Bazzan M; Fantino G
    Thromb Haemost; 2008 Apr; 99(4):779-81. PubMed ID: 18392338
    [No Abstract]   [Full Text] [Related]  

  • 18. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients.
    Cegarra-Sanmartín V; González-Rodríguez R; Paniagua-Iglesias P; Santamaría-Ortiz A; Cueva LF; Galán-Serrano J; Moral-García MV
    J Cardiothorac Vasc Anesth; 2014 Aug; 28(4):1008-12. PubMed ID: 24439171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
    Parody R; Oliver A; Souto JC; Fontcuberta J
    Haematologica; 2003 Nov; 88(11):ECR32. PubMed ID: 14607764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
    Cines DB; Rauova L; Arepally G; Reilly MP; McKenzie SE; Sachais BS; Poncz M
    J Clin Apher; 2007 Feb; 22(1):31-6. PubMed ID: 17285619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.